Effectiveness of a Serogroup B and C Meningococcal Vaccine Developed in Cuba.
CONCLUSIONS In addition to prevention of meningococcal disease caused by homologous serogroup B strains, VA-MENGOC-BC should be considered for heterologous contexts. It is protective against serogroup C in all age groups. KEYWORDS Neisseria meningitidis, meningococcal disease, meningococcal vaccines, serogroup B meningococcus, serogroup C meningococcus, immunogenicity, bacterial outer membrane proteins, heterologous effects of vaccines, acellular vaccines, Cuba.
PMID: 31242158 [PubMed - in process]
Source: MEDICC Review - Category: International Medicine & Public Health Tags: MEDICC Rev Source Type: research
More News: Brazil Health | Children | Colombia Health | Cuba Health | International Medicine & Public Health | Men | Meningitis | Meningitis Vaccine | Outbreaks | Study | Uruguay Health | Vaccines